CME Information

Target Audience
This self-study activity is designed for podiatrists, internists, family practitioners, and surgeons involved in the care and treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.

Program Overview
The burden of nosocomial infections in surgical patients today is alarming. Approximately 70 percent of nosocomial infections are due to gram-positive organisms, with MRSA being a very common nosocomial pathogen in hospitalized patients and the most common nosocomial pathogen in surgical patients.

Equally alarming is the recent, rapidly rising prevalence of community-acquired MRSA (CA-MRSA), a pathogen that appears to have evolved independently of healthcare-associated MRSA (HA-MRSA). CA-MRSA has a higher susceptibility to antistaphylococcal antibiotics compared with HA-MRSA, but many strains are extremely virulent, causing necrotizing fasciitis and pneumonia in otherwise healthy individuals.

Since the presentation and management of HA-MRSA and CA-MRSA infections can be quite different, it is of the utmost importance that surgeons are familiar with both groups of infections. This article will review the epidemiology, detection, prevention, and management of HA-MRSA and CA-MRSA in surgical patients.

Format
This self-study activity includes supporting figures and tables. A Post-Test to review knowledge of the important points and an Evaluation Form of this continuing medical education (CME) activity are also included. Completing this CME activity requires reading the self-study portion and completing the Post-Test and Evaluation Form. This CME activity may take up to 2 hours to complete.

This CME activity will discuss the most recent data on the epidemiology and current treatment options for MRSA infections.

The purpose of this publication is to disseminate important information from the symposium “Evaluating Strategies to Improve Patient Outcomes: Community-Acquired and Healthcare-Associated MRSA,” held October 18, 2005, in connection with the American College of Surgeons meeting, to the physicians who were unable to attend.

Educational Objectives
At the conclusion of this program, participants should be able to:
• Recognize the threat of HA-MRSA and CA-MRSA in the surgical setting and implement strategies to minimize this threat
• Differentiate infections due to HA-MRSA versus those due to CA-MRSA
• Evaluate the utility of anti-MRSA agents for empiric and directed therapy in patients with HA-MRSA and CA-MRSA

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin School of Medicine and Public Health and Rxperience. The University of Wisconsin School of Medicine and Public Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of Wisconsin School of Medicine and Public Health designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Wisconsin-Madison, as a member of the University Continuing Education Association (UCEA), authorizes this program for 0.2 Continuing Education Units (CEUs) or 2 hours.

Credit for participating in this CME activity is available from December 1, 2006 to November 30, 2007.

Faculty And Sponsor Disclosure
As a sponsor accredited by the ACCME, it is the policy of the University of Wisconsin School of Medicine and Public Health to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with either the commercial supporter(s) of this activity or the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

Kamal M.F. Itani, MD, FACS, has disclosed that he has received research support from Merck & Co., Inc., Pfizer Inc, Theravance, Inc., and Wyeth, and is on the speakers bureau for Pfizer Inc.

Add new comment